Daniel Lindholm1,2, Stefan K James1,2, Katja Gabrysch2, Robert F Storey3, Anders Himmelmann4, Christopher P Cannon5,6, Kenneth W Mahaffey7, Philippe Gabriel Steg8,9,10, Claes Held1,2, Agneta Siegbahn2,11, Lars Wallentin1,2. 1. Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden. 2. Uppsala Clinical Research Center, Uppsala, Sweden. 3. Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom. 4. AstraZeneca Research and Development, Mölndal, Sweden. 5. Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. 6. Baim Clinical Research Institute, Boston, Massachusetts. 7. Stanford Center for Clinical Research, Stanford School of Medicine, Stanford, California. 8. Assistance Publique-Hôpitaux de Paris; Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France. 9. Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France. 10. NHLI Imperial College, ICMS, Royal Brompton Hospital, London, United Kingdom. 11. Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Abstract
Importance: Mortality remains at about 5% within a year after an acute coronary syndrome event. Prior studies have assessed biomarkers in relation to all-cause or cardiovascular deaths but not across multiple causes. Objective: To assess if different biomarkers provide information about the risk for all-cause and cause-specific mortality. Design, Setting, and Participants: The Platelet Inhibition and Patient Outcomes (PLATO) trial randomized 18 624 patients with acute coronary syndrome to ticagrelor or clopidogrel from October 2006 through July 2008. In this secondary analysis biomarker substudy, 17 095 patients participated. Main Outcomes and Measures: Death due to myocardial infarction, heart failure, sudden cardiac death/arrhythmia, bleeding, procedures, other vascular causes, and nonvascular causes, as well as all-cause death. Exposures: At baseline, levels of cystatin-C, growth differentiation factor-15 (GDF-15), high-sensitivity C-reactive protein, high-sensitivity troponin I and T, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were determined. Results: The median (interquartile range) age of patients was 62.0 (54.0-71.0) years. Of 17 095 patients, 782 (4.6%) died during follow-up. The continuous associations between biomarkers and all-cause and cause-specific mortality were modeled using Cox models and presented as hazard ratio (HR) comparing the upper vs lower quartile. For all-cause mortality, NT-proBNP and GDF-15 were the strongest markers with adjusted HRs of 2.96 (95% CI, 2.33-3.76) and 2.65 (95% CI, 2.17-3.24), respectively. Concerning death due to heart failure, NT-proBNP was associated with an 8-fold and C-reactive protein, GDF-15, and cystatin-C, with a 3-fold increase in risk. Regarding sudden cardiac death/arrhythmia, NT-proBNP was associated with a 4-fold increased risk and GDF-15 with a doubling in risk. Growth differentiation factor-15 had the strongest associations with other vascular and nonvascular deaths and was possibly associated with death due to major bleeding (HR, 4.91; 95% CI, 1.39-17.43). Conclusions and Relevance: In patients with acute coronary syndrome, baseline levels of NT-proBNP and GDF-15 were strong markers associated with all-cause death based on their associations with death due to heart failure as well as due to arrhythmia and sudden cardiac death. Growth differentiation factor-15 had the strongest associations with death due to other vascular or nonvascular causes and possibly with death due to bleeding. Trial Registration: ClinicalTrials.gov Identifier: NCT00391872.
RCT Entities:
Importance: Mortality remains at about 5% within a year after an acute coronary syndrome event. Prior studies have assessed biomarkers in relation to all-cause or cardiovascular deaths but not across multiple causes. Objective: To assess if different biomarkers provide information about the risk for all-cause and cause-specific mortality. Design, Setting, and Participants: The Platelet Inhibition and Patient Outcomes (PLATO) trial randomized 18 624 patients with acute coronary syndrome to ticagrelor or clopidogrel from October 2006 through July 2008. In this secondary analysis biomarker substudy, 17 095 patients participated. Main Outcomes and Measures: Death due to myocardial infarction, heart failure, sudden cardiac death/arrhythmia, bleeding, procedures, other vascular causes, and nonvascular causes, as well as all-cause death. Exposures: At baseline, levels of cystatin-C, growth differentiation factor-15 (GDF-15), high-sensitivity C-reactive protein, high-sensitivity troponin I and T, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were determined. Results: The median (interquartile range) age of patients was 62.0 (54.0-71.0) years. Of 17 095 patients, 782 (4.6%) died during follow-up. The continuous associations between biomarkers and all-cause and cause-specific mortality were modeled using Cox models and presented as hazard ratio (HR) comparing the upper vs lower quartile. For all-cause mortality, NT-proBNP and GDF-15 were the strongest markers with adjusted HRs of 2.96 (95% CI, 2.33-3.76) and 2.65 (95% CI, 2.17-3.24), respectively. Concerning death due to heart failure, NT-proBNP was associated with an 8-fold and C-reactive protein, GDF-15, and cystatin-C, with a 3-fold increase in risk. Regarding sudden cardiac death/arrhythmia, NT-proBNP was associated with a 4-fold increased risk and GDF-15 with a doubling in risk. Growth differentiation factor-15 had the strongest associations with other vascular and nonvascular deaths and was possibly associated with death due to major bleeding (HR, 4.91; 95% CI, 1.39-17.43). Conclusions and Relevance: In patients with acute coronary syndrome, baseline levels of NT-proBNP and GDF-15 were strong markers associated with all-cause death based on their associations with death due to heart failure as well as due to arrhythmia and sudden cardiac death. Growth differentiation factor-15 had the strongest associations with death due to other vascular or nonvascular causes and possibly with death due to bleeding. Trial Registration: ClinicalTrials.gov Identifier: NCT00391872.
Authors: Christoph Varenhorst; Ulrica Alström; Oscar Ö Braun; Robert F Storey; Kenneth W Mahaffey; Maria Bertilsson; Christopher P Cannon; Benjamin M Scirica; Anders Himmelmann; Stefan K James; Lars Wallentin; Claes Held Journal: Heart Date: 2014-06-23 Impact factor: 5.994
Authors: Ziad Hijazi; Jonas Oldgren; Johan Lindbäck; John H Alexander; Stuart J Connolly; John W Eikelboom; Michael D Ezekowitz; Claes Held; Elaine M Hylek; Renato D Lopes; Agneta Siegbahn; Salim Yusuf; Christopher B Granger; Lars Wallentin Journal: Lancet Date: 2016-04-04 Impact factor: 79.321
Authors: Paul J Emmerson; Feng Wang; Yong Du; Qian Liu; Richard T Pickard; Malgorzata D Gonciarz; Tamer Coskun; Matthew J Hamang; Dana K Sindelar; Kimberly K Ballman; Lisa A Foltz; Avinash Muppidi; Jorge Alsina-Fernandez; Gavin C Barnard; Jason X Tang; Xilin Liu; Xudong Mao; Robert Siegel; John H Sloan; Pamela J Mitchell; Bei B Zhang; Ruth E Gimeno; Bei Shan; Xinle Wu Journal: Nat Med Date: 2017-08-28 Impact factor: 53.440
Authors: Emil Hagström; Claes Held; Ralph A H Stewart; Philip E Aylward; Andrzej Budaj; Christopher P Cannon; Wolfgang Koenig; Sue Krug-Gourley; Emile R Mohler; Philippe Gabriel Steg; Elizabeth Tarka; Ollie Östlund; Harvey D White; Agneta Siegbahn; Lars Wallentin Journal: Clin Chem Date: 2016-11-03 Impact factor: 8.327
Authors: J A de Lemos; D A Morrow; J H Bentley; T Omland; M S Sabatine; C H McCabe; C Hall; C P Cannon; E Braunwald Journal: N Engl J Med Date: 2001-10-04 Impact factor: 91.245
Authors: John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile Journal: N Engl J Med Date: 2014-08-30 Impact factor: 91.245
Authors: Daniel Lindholm; Stefan K James; Maria Bertilsson; Richard C Becker; Christopher P Cannon; Evangelos Giannitsis; Robert A Harrington; Anders Himmelmann; Frederic Kontny; Agneta Siegbahn; Philippe Gabriel Steg; Robert F Storey; Matthijs A Velders; W Douglas Weaver; Lars Wallentin Journal: Clin Chem Date: 2016-12-08 Impact factor: 8.327
Authors: Ida Gregersen; Annika E Michelsen; Ngoc Nguyen Lunde; Axel Åkerblom; Tatevik G Lakic; Mona Skjelland; Karolina Ryeng Skagen; Richard C Becker; Johan Lindbäck; Anders Himmelmann; Rigmor Solberg; Harald T Johansen; Stefan K James; Agneta Siegbahn; Robert F Storey; Frederic Kontny; Pål Aukrust; Thor Ueland; Lars Wallentin; Bente Halvorsen Journal: J Am Heart Assoc Date: 2020-08-15 Impact factor: 5.501